Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Correlation between Plasma Soluble CD36 Levels with Body Mass Index of Breast Cancer Patients in the Indonesian Population

Indonesian Journal of Cancer Chemoprevention · Vol. 14 No. 1 (2023) · hlm. 12–21

DOI
10.14499/indonesianjcanchemoprev14iss1pp12-21
ISSN
2355-8989, 2088-0197
Terbit
2023-02-28
Penerbit
Indonesian Society for Cancer Chemoprevention
Bahasa
eng

Abstrak

The cluster of differentiation 36 (CD36) is a multiligand receptor protein that plays a role in lipid metabolism. Its biological functions involve lipid uptake, immune recognition, inflammation, molecular adhesion, and tumor metastasis. Soluble CD36 (sCD36) is the circulating form of CD36 in plasma. Research on the role of sCD36 in breast cancer is limited. This study aimed to investigate sCD36 concentration and evaluate the correlation between sCD36 concentration and BMI in breast cancer patients. This is a multi-center cross-sectional study done from June 2018 to February 2019 in Indonesia. Consecutive sampling was done for women with invasive breast cancer aged 18-70. Patients with locoregional recurrences, multiple comorbidities, diabetes, stroke, or liver impairment were excluded. Patients were grouped based on their BMI into normo-weight and overweight/obese. Plasma sCD36 was analyzed using Bioassay Laboratory™ ELISA. The correlation between plasma sCD36 and the patient's characteristics (metastasis status and molecular subtype) were then analyzed. A total of 76 patients were enrolled, 36 of whom were categorized into the overweight/obese group and 40 of them in the normo-weight. Plasma levels of sCD36 in breast cancer patients were higher than controls at 0.24±0.163 ng/mL and 0.46±0.175 ng/mL, respectively (p=0.006). However, no difference in plasma sCD36 levels was found between the overweight/obese group and the normo-weight breast cancer subjects (p>0.05). Plasma sCD36 increased significantly in breast cancer patients, but no significant difference was found based on body mass index. Further research is needed to determine the role of sCD36 in determining clinical outcomes and prognosis in breast cancer patients.Keywords: Soluble CD36, body mass index, breast cancer, indonesia.

Jaringan kolaborasi para penulis

16 penulis · 32 tautan kepenulisan bersama · 11 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo
  • Diponegoro University
  • Padjadjaran University
  • Universitas Airlangga
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Muhammad Hasan BashariPadjadjaran University1
Julia RamadhantiPadjadjaran University1
Kharima Dwi UtamiPadjadjaran University1
Patricia Diana PrasetiyoDiponegoro University1
Ika PawitraDiponegoro University1
Liza Suryani DewiDiponegoro University1
Noor WidjayahadiDiponegoro University1
Putri Aliya AhadiniUniversitas Airlangga1
Harry YusufRumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo1
Maruhum Bonar Hasiholan MarbunRumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo1
Hamzah ShatriRumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://ijcc.chemoprev.org/index.php/ijcc/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Correlation between Plasma Soluble CD36 Levels with Body Mass Index of Breast Cancer Patients in the Indonesian Population</dc:title>
	<dc:creator>Rachman, Andhika</dc:creator>
	<dc:creator>Irawan, Cosphiadi</dc:creator>
	<dc:creator>R.R., Aditia</dc:creator>
	<dc:creator>Koesnoe, Sukamto</dc:creator>
	<dc:creator>Wijaya, Indra</dc:creator>
	<dc:description xml:lang="en-US">The cluster of differentiation 36 (CD36) is a multiligand receptor protein that plays a role in lipid metabolism. Its biological functions involve lipid uptake, immune recognition, inflammation, molecular adhesion, and tumor metastasis. Soluble CD36 (sCD36) is the circulating form of CD36 in plasma. Research on the role of sCD36 in breast cancer is limited. This study aimed to investigate sCD36 concentration and evaluate the correlation between sCD36 concentration and BMI in breast cancer patients. This is a multi-center cross-sectional study done from June 2018 to February 2019 in Indonesia. Consecutive sampling was done for women with invasive breast cancer aged 18-70. Patients with locoregional recurrences, multiple comorbidities, diabetes, stroke, or liver impairment were excluded. Patients were grouped based on their BMI into normo-weight and overweight/obese. Plasma sCD36 was analyzed using Bioassay Laboratory™ ELISA. The correlation between plasma sCD36 and the patient's characteristics (metastasis status and molecular subtype) were then analyzed. A total of 76 patients were enrolled, 36 of whom were categorized into the overweight/obese group and 40 of them in the normo-weight. Plasma levels of sCD36 in breast cancer patients were higher than controls at 0.24±0.163 ng/mL and 0.46±0.175 ng/mL, respectively (p=0.006). However, no difference in plasma sCD36 levels was found between the overweight/obese group and the normo-weight breast cancer subjects (p&gt;0.05). Plasma sCD36 increased significantly in breast cancer patients, but no significant difference was found based on body mass index. Further research is needed to determine the role of sCD36 in determining clinical outcomes and prognosis in breast cancer patients.Keywords: Soluble CD36, body mass index, breast cancer, indonesia.</dc:description>
	<dc:publisher xml:lang="en-US">Indonesian Society for Cancer Chemoprevention</dc:publisher>
	<dc:contributor xml:lang="en-US"></dc:contributor>
	<dc:date>2023-02-28</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US"></dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijcc.chemoprev.org/index.php/ijcc/article/view/433</dc:identifier>
	<dc:identifier>10.14499/indonesianjcanchemoprev14iss1pp12-21</dc:identifier>
	<dc:source xml:lang="en-US">Indonesian Journal of Cancer Chemoprevention; Vol 14, No 1 (2023); 12-21</dc:source>
	<dc:source>2355-8989</dc:source>
	<dc:source>2088-0197</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijcc.chemoprev.org/index.php/ijcc/article/view/433/271</dc:relation>
	<dc:relation>https://ijcc.chemoprev.org/index.php/ijcc/article/downloadSuppFile/433/43</dc:relation>
	<dc:relation>https://ijcc.chemoprev.org/index.php/ijcc/article/downloadSuppFile/433/44</dc:relation>
	<dc:relation>https://ijcc.chemoprev.org/index.php/ijcc/article/downloadSuppFile/433/45</dc:relation>
	<dc:relation>https://ijcc.chemoprev.org/index.php/ijcc/article/downloadSuppFile/433/46</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2023 Indonesian Journal of Cancer Chemoprevention</dc:rights>
</oai_dc:dc>